bpc-157 dosage for tendon repair Dosing (Common Protocols), πΉ Oral / Subcutaneous, β’ 500 mcg daily, β’ Duration: 6 weeks, πΉ Intramuscular / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA or bpc 157 dose cycle BPC-157:
Description
It is important to review your policy or contact United Healthcare directly to understand the extent of your coverage, including any limitations, co-pays, or deductibles that may apply

Apart from tender muscle at the injection site, normally no

AAFP (2017, with ongoing relevance)

Stable conditions support safe BAC water use across treatment periods

Being unregulated, the peptide vials one buys may be of questionable purity or dosage
